- CA$28.52m
- CA$28.36m
- CA$0.10m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 122.35 | ||
| Price to Tang. Book | 122.35 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 274.77 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -736.82% | ||
| Return on Equity | n/a | ||
| Operating Margin | -3684.12% | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.27 | 0.44 | 0.49 | 0.17 | 0.1 | n/a | n/a | -20.72% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Diagnos Inc. is a Canadian company, which is engaged in the early detection of critical eye-related health problems using advanced technology based on Artificial Intelligence (AI). It markets Computer Assisted Retinal Analysis (CARA), a software platform which assists health specialists in the detection of certain retinopathy pathologies through the computerized analysis of retina images. CARA is an in-house-hosted Web-based application that integrates fundus cameras with an image processing engine over a secure Internet connection. The CARA suite of applications allows an eye care specialist to more clearly visualize both normal retinal landmarks (optic nerve, vascular system, macula, fovea), and pathological changes (exudates, haemorrhages, micro-aneurisms, neo-vascularization). CARA is indicated for use by healthcare professionals in an adult general population in the context of a general eye-health exam.
Directors
- Vincent Duhamel CHM
- Andre Larente PRE
- Marc-andre Massue CFO
- Francis Bellido IND
- Robert Dunn IND
- Reid Maclellan IND
- Last Annual
- March 31st, 2025
- Last Interim
- March 31st, 2025
- Incorporated
- April 11th, 1996
- Public Since
- September 27th, 2000
- Sector
- Software & IT Services
- Industry
- Technology
- Exchange
TSX Venture Exchange- Shares in Issue
- 101,862,977
- Address
- 7005 Taschereau Blvd Suite 340, BROSSARD, J4Z 1A7
- Web
- https://www.diagnos.com/
- Phone
- +1 4506788882
- Auditors
- Raymond Chabot Grant Thornton LLP
Latest News for ADK
Upcoming Events for ADK
Q1 2026 Diagnos Inc Earnings Release
Diagnos Inc Annual Shareholders Meeting
Q2 2026 Diagnos Inc Earnings Release
Similar to ADK
01 Communique Laboratory
TSX Venture Exchange
Acceleware
TSX Venture Exchange
AGEDB Technology
TSX Venture Exchange
Aisix Solutions
TSX Venture Exchange
AnalytixInsight
TSX Venture Exchange
FAQ
As of Today at 20:13 UTC, shares in Diagnos are trading at CA$0.28. This share price information is delayed by 15 minutes.
Shares in Diagnos last closed at CA$0.28 and the price had moved by -13.85% over the past 365 days. In terms of relative price strength the Diagnos share price has underperformed the Toronto Stock Exchange 300 Composite Index by -28.82% over the past year.
The overall consensus recommendation for Diagnos is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreDiagnos does not currently pay a dividend.
Diagnos does not currently pay a dividend.
Diagnos does not currently pay a dividend.
To buy shares in Diagnos you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.28, shares in Diagnos had a market capitalisation of CA$28.52m.
Here are the trading details for Diagnos:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: ADK
Based on an overall assessment of its quality, value and momentum Diagnos is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Diagnos is CA$1.50. That is 435.71% above the last closing price of CA$0.28.
Analysts covering Diagnos currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Diagnos. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -23.18%.
As of the last closing price of CA$0.28, shares in Diagnos were trading +1.17% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Diagnos PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.28.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Diagnos' management team is headed by:
- Vincent Duhamel - CHM
- Andre Larente - PRE
- Marc-andre Massue - CFO
- Francis Bellido - IND
- Robert Dunn - IND
- Reid Maclellan - IND